Showing results (1-10 of 15) with videos related to

Sort By:
Pageof 2
Journal of Circulating Biomarkers|March 15, 2021
Development of an immunofluorescent AR-V7 circulating tumor cell assay - A blood-based test for men with metastatic prostate cancerDavid Lu, Rachel Krupa, Melissa Harvey, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 17, 2015
The Initial Detection and Partial Characterization of Circulating Tumor Cells in Neuroendocrine Prostate CancerHimisha Beltran, Adam Jendrisak, Mark Landers, et al.
BMC Cancer|September 24, 2016
Programmed death-ligand 1 (PD-L1) characterization of circulating tumor cells (CTCs) in muscle invasive and metastatic bladder cancer patientsArchana Anantharaman, Terence Friedlander, David Lu, et al.
NPJ Precision Oncology|August 13, 2021
Circulating tumor cell heterogeneity in neuroendocrine prostate cancer by single cell copy number analysisVincenza Conteduca, Sheng-Yu Ku, Luisa Fernandez, et al.
JCO Precision Oncology|August 25, 2020
Circulating Tumor Cells as a Predictor of Treatment Response in Clinically Localized Prostate CancerSimpa S Salami, Udit Singhal, Daniel E Spratt, et al.
Cancer Research|August 21, 2020
Morphology-Predicted Large-Scale Transition Number in Circulating Tumor Cells Identifies a Chromosomal Instability Biomarker Associated with Poor Outcome in Castration-Resistant Prostate CancerJoseph D Schonhoft, Jimmy L Zhao, Adam Jendrisak, et al.
JAMA Oncology|June 5, 2016
Association of AR-V7 on Circulating Tumor Cells as a Treatment-Specific Biomarker With Outcomes and Survival in Castration-Resistant Prostate CancerHoward I Scher, David Lu, Nicole A Schreiber, et al.
Cancer Research|August 19, 2017
Phenotypic Heterogeneity of Circulating Tumor Cells Informs Clinical Decisions between AR Signaling Inhibitors and Taxanes in Metastatic Prostate CancerHoward I Scher, Ryon P Graf, Nicole A Schreiber, et al.
The Prostate|February 26, 2021
Nivolumab plus ipilimumab, with or without enzalutamide, in AR-V7-expressing metastatic castration-resistant prostate cancer: A phase-2 nonrandomized clinical trialEugene Shenderov, Karim Boudadi, Wei Fu, et al.
BJU International|August 20, 2016
Phenotypic diversity of circulating tumour cells in patients with metastatic castration-resistant prostate cancerAndrew S McDaniel, Roberta Ferraldeschi, Rachel Krupa, et al.
Pageof 2